Physician profile
Olivia L Lee
NPI 1134279995
$15,751.31
in general payments reported to CMS, 2019-2025
20 companies · $13K in 2025
The $13K reported for 2025 was more than what 83% of Uveitis and Ocular Inflammatory Disease providers received nationally (typical 2025 total: $471).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $56.83 · 2021: $334 · 2022: $722 · 2023: $859 · 2024: $839 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,400 · Food and Beverage: $3,249 · Honoraria: $2,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,400.00 |
| Food and Beverage | $3,248.97 |
| Honoraria | $2,625.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $8,602.36 | 2024-2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $2,784.86 | 2025 | Purified Cortrophin Gel |
| Sun Pharmaceutical Industries INC. | $697.89 | 2020-2025 | Cequa |
| Glaukos Corporation | $640.76 | 2020-2024 | Istent Trabecular Micro-Bypass System Model Is3, Idose |
| Sentynl Therapeutics, INC. | $583.00 | 2022 | |
| Bausch & Lomb Americas INC. | $405.27 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Mallinckrodt Hospital Products INC. | $362.09 | 2023-2025 | Acthar |
| Alcon Vision LLC | $317.09 | 2021-2025 | Tryptyr, Centurion, Clareon |
| Harrow Eye, LLC | $273.73 | 2024-2025 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $195.83 | 2019 | |
| Horizon Therapeutics Plc | $150.00 | 2023 | Tepezza |
| Genentech, INC. | $135.43 | 2024 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $97.46 | 2019 | |
| Rxsight INC | $97.43 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Oyster Point Pharma, INC. | $89.37 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $88.80 | 2023 | Cystadrops, Carbaglu, Cystadane |
| Abbvie INC. | $87.41 | 2023-2024 | |
| Lilly USA, LLC | $70.80 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $47.24 | 2023 | Artevo 800 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.